Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Avaronnan, Manuprasad"'
Autor:
Goyal, Gautam, Singh, Ashish, Avaronnan, Manuprasad, Raut, Nirmal Vivek, Talreja, Vikas, Chandrasekharan, Arun, Gupta, Kushal, Bhosale, Bharat, Kothari, Rushabh Kiran, Parekh, Deevyashali, Poladia, Bhavesh Pradip, Ghosh, Joydeep, Talele, Avinash, Shrirangwar, Sameer, Karpe, Akshay
Publikováno v:
In The Lancet Regional Health - Southeast Asia May 2024 24
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 1, Pp 13-18 (2020)
Introduction: Salvage chemotherapy followed by autologous stem cell transplantation is the standard of care in relapsed lymphoma. The optimal regimen for salvage is not defined. The combination of gemcitabine, dexamethasone, and cisplatin (GDP) is an
Externí odkaz:
https://doaj.org/article/fa7fdbb2b90b491a957a127ce732f5b8
Autor:
Avaronnan Manuprasad, Praveen Kumar Shenoy, Joneetha Jones, N V Vinin, Adarsh Dharmarajan, Geetha Muttath
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 1, Pp 69-73 (2020)
Introduction: Majority of the patients in low-to-middle income countries (LMICs) have no access to adjuvant trastuzumab due to financial constraints. Short-course (9 weeks) schedule of trastuzumab is a feasible alternative in this setting. The object
Externí odkaz:
https://doaj.org/article/cc2c694ac2394807abdbb95d21bb487d
Autor:
Avaronnan Manuprasad, Venkatraman Radhakrishnan, Sunil B. J, A.S. Ramakrishnan, T.S. Ganesan, Prasanth Ganesan, Jaikumar Ramamurthy, Manikandan Dhanushkodi, T.G. Sagar
Publikováno v:
Pediatric Hematology Oncology Journal, Vol 3, Iss 1, Pp 13-16 (2018)
Background: Hepatoblastoma is a rare pediatric tumor arising from the liver. The present study was conducted to ascertain the clinical profile and survival outcomes of patients with hepatoblastoma treated at our centre. Methods: We collected the case
Externí odkaz:
https://doaj.org/article/d91ea34036494da9a564979d7b29a499
Autor:
Vineetha Raghavan, Avaronnan Manuprasad, P B Sajeev Kumar, Zoheb Raj, Praveen Kumar Shenoy, Chandran K Nair
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 1, Iss 2, Pp 92-95 (2018)
Background: Multiple myeloma is a disease where health-related quality of life (HRQoL) is an important treatment end point. There are limited quality of life data of patients on novel antimyeloma agents, especially from developing countries. Methods:
Externí odkaz:
https://doaj.org/article/d67a3f7b19554982adb9da5477d4fe5c
Autor:
Praveen Kumar Shenoy V P, Vineetha Raghavan, Avaronnan Manuprasad, Sajeev Kumar P. B., Zoheb Raj, Chandran K. Nair
Publikováno v:
Indian Journal of Medical and Paediatric Oncology. 43:355-360
Introduction Psychosocial concerns especially fear of cancer recurrence (FCR) is less commonly addressed among patients with multiple myeloma in India. Myeloma being incurable, an understanding of this problem is essential for adequately addressing t
Autor:
Avaronnan Manuprasad, Praveen Kumar Shenoy, Joneetha Jones, N V Vinin, Adarsh Dharmaraj, Geetha Muttath
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 3, Iss 2, Pp 402-403 (2020)
Externí odkaz:
https://doaj.org/article/41307b415fb04b27ab7a38e67e6d3535
Autor:
Jose, Nisha K., Soman, Biju, Thulaseedharan, Jissa V., Varghese, Bipin T., Thomas, Shaji, Tom, Jeremiah J., Warrier, Narayanankutty, Avaronnan, Manuprasad, Jeemon, Panniyammakal
Publikováno v:
Journal of Family Medicine & Primary Care; Oct2023, Vol. 12 Issue 10, p2501-2506, 6p
Autor:
V P Praveen Kumar, Shenoy, Avaronnan, Manuprasad, Sajith, Babu, Sithara, Aravind, Vinin N, Narayanan, Sangeetha, Nayanar, Satheesan, Balasubramanian
Publikováno v:
ecancermedicalscience. 16
Surgery is an important component of multimodality treatment in advanced oral cavity cancers. But in low-middle-income countries like India, with limited centres offering complex head and neck surgeries, prolonged waiting times for surgery is a major
Publikováno v:
Supportive Care in Cancer. 28:5449-5454
A large number of AML patients present with infection at the time of initial presentation in Indian settings. There is lack of published data on the proportion of patients with infection at initial presentation and its impact on induction mortality.